Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine.
Solubility and dissolution relationships in the gastrointestinal tract can be critical for the oral bioavailability of poorly soluble drugs. In the case of poorly soluble weak bases, the possibility of drug precipitation upon entry into the small intestine may also affect the amount of drug available for uptake through the intestinal mucosa. To simulate the transfer out of the stomach into the intestine, a transfer model was devised, in which a solution of the drug in simulated gastric fluid is continuously pumped into a simulated intestinal fluid, and drug precipitation in the acceptor medium is examined via concentration-time measurements. The in-vitro precipitation of three poorly soluble weakly basic drugs, dipyridamole, BIBU 104 XX and BIMT 17 BS, was investigated. For all three, extensive supersaturation was achieved in the acceptor medium. Under simulated fasted-state conditions, precipitation occurred for all three compounds whereas under simulated fed-state conditions, the higher concentrations of bile components and the lower pH value in the acceptor medium inhibited precipitation at concentrations corresponding to usual doses in all cases. Comparison with pharmacokinetic data indicated that a combination of transfer model data with solubility and dissolution profiles should lead to better predictions of in-vivo behaviour of poorly soluble weak bases.
Kostewicz
Edmund S
ES
Department of Pharmaceutical Technology, J. W. Goethe University, Marie-Curie Str. 9, D-60439 Frankfurt am Main, Germany.
Wunderlich
Martin
M
Brauns
Ulrich
U
Becker
Robert
R
Bock
Thomas
T
Dressman
Jennifer B
JB
D001562:Benzimidazoles / Q000737:chemistry* / Q000493:pharmacokinetics; D001646:Bile / Q000737:chemistry; D001713:Biphenyl Compounds / Q000737:chemistry* / Q000493:pharmacokinetics; D011232:Chemical Precipitation; D004176:Dipyridamole / Q000737:chemistry* / Q000493:pharmacokinetics; D005215:Fasting; D005753:Gastric Mucosa / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D007421:Intestine, Small / Q000378:metabolism; D008954:Models, Biological; D011759:Pyrrolidines / Q000737:chemistry* / Q000493:pharmacokinetics; D012995:Solubility; D013270:Stomach
D001562:Benzimidazoles; D001713:Biphenyl Compounds; D011759:Pyrrolidines; C107918:lefradafiban; C098107:flibanserin; D004176:Dipyridamole